• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

Premarket Approval (PMA)

  • Print
  • Share
  • E-mail
-
Super Search Devices@FDA
510(k) | DeNovo | Registration & Listing | Adverse Events | Recalls | PMA | HDE | Classification | Standards
CFR Title 21 | Radiation-Emitting Products | X-Ray Assembler | Medsun Reports | CLIA | TPLC
 


New Search Back to Search Results
Note: this medical device has supplements. The device description may have changed. Be sure to look at the supplements to get an up-to-date view of this device.
 
DeviceCOBAS KRAS MUTATION TEST
Classification Namesomatic gene mutation detection system
Generic Namesomatic gene mutation detection system
Applicant
Roche Molecular Systems, Inc.
4300 hacienda drive
pleasanton, CA 94588-2722
PMA NumberP140023
Date Received10/23/2014
Decision Date05/07/2015
Product Code
OWD[ Registered Establishments with OWD ]
Docket Number 15M-1708
Notice Date 05/18/2015
Advisory Committee Pathology
Expedited Review Granted? No
Combination Product No
Approval Order Statement 
Approval for the cobas kras mutation test. This device is indicated for the following:the cobas kras mutation test, for use with the cobas 4800 system, is a real-time pcr test for the detection of seven somatic mutations in codons 12 and 13 of the kras gene in dna derived from formalin-fixed paraffin-embedded human colorectal cancer (crc) tumor tissue. The test is intended to be used as an aid in the identification of crc patients for whom treatment with erbitux (cetuximab) or with vectibix (panitumumab) may be indicated based on a no mutation detected result. Specimens are processed using the cobas dna sample preparation kit for manual sample preparation and the cobas z 480 analyzer for automated amplification and detection.
Approval Order Approval Order
Summary Summary of Safety and Effectiveness
Labeling Labeling
Supplements: S001 S002 S003 S005 S006 
-
-